Steven C. Gilman, Director at Akebia Therapeutics, Inc. (AKBA), sold 4,567 shares at $0.36 ($2K) on 2022-06-03, disclosed to the SEC on 2022-06-07.
Scheduled sale ($2k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| VCEL | SELL | 2024-09-20 | $531K | — | Filing → |
| VCEL | SELL | 2024-09-05 | $243K | — | Filing → |
| VCEL | SELL | 2022-05-02 | $28K | — | Filing → |